Microdose drug test aims to find best cancer fighters

NCT ID NCT06366451

Completed Knowledge-focused Sponsor: Presage Biosciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested very small amounts of several cancer drugs (rilvegostomig, volrustomig, sabestomig, AZD9592, and pembrolizumab) injected directly into head and neck tumors in 17 people. The goal was to see how each drug affects the tumor's environment at the injection site. This approach helps researchers compare drugs quickly without exposing patients to full doses, but it cannot determine if the drugs actually treat the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rilvegostomig, volrustomig, sabestomig, AZD9592, and pembrolizumab (Keytruda)
What this could lead to: If successful, this study could help identify which drugs are most promising for treating head and neck cancer, guiding future larger trials.
What could go wrong: This is a very early (Phase 0) study with only 17 people, so it cannot prove any drug works. It only looks at immediate effects in the tumor, not long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Head and Neck Neoplasms head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK SQUAMOUS CELL CARCINOMA

Contacts and locations

Locations

Medical University of South Carolina

Charleston, South Carolina, 29407, United States
Montefiore Medical Center

The Bronx, New York, 10467, United States
Oregon Health & Science University (OHSU)

Portland, Oregon, 97239, United States
Sarah Cannon Medical Center

Charleston, South Carolina, 29406, United States
UC Davis

Sacramento, California, 95817, United States
University of North Carolina

Chapel Hill, North Carolina, 27599, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.